NeuroPharma AB
This article was originally published in Start Up
Executive Summary
There is presently no treatment specifically approved to halt the neurological damage that continues for hours and days in the wake of a brain injury. But there is an already-approved compound that some scientists and clinicians believe will prove helpful. The backers of NeuroPharma are betting that a new formulation of cyclosporin, the drug long used to prevent rejection of transplanted organs, can be shown to have a beneficial effect on people with TBI.
You may also be interested in...
Start-Up Previews (01/07)
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile groups are "Treating Traumatic Brain Injury," with profiles of Banyan Biomarkers, NeuroPharma AB, and RemeGenix; and "Can Stents Pull Off a Disappearing Act?," with profiles of Amaranth Medical, Bioabsorbable Therapeutics, and TissueGen Plus these Start-Ups Across Health Care: Design Medical, Kythera Biopharmaceuticals and Plethora Solutions.
Treating Traumatic Brain Injury
Past failures guide start-ups that seek to develop drugs for this silent epidemic, but will investors follow?
Start-Up Previews (01/07)
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile groups are "Treating Traumatic Brain Injury," with profiles of Banyan Biomarkers, NeuroPharma AB, and RemeGenix; and "Can Stents Pull Off a Disappearing Act?," with profiles of Amaranth Medical, Bioabsorbable Therapeutics, and TissueGen Plus these Start-Ups Across Health Care: Design Medical, Kythera Biopharmaceuticals and Plethora Solutions.